BioAge Labs Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 clinical trial for BGE-102, an innovative, orally available small molecule inhibitor of NLRP3. This novel inhibitor demonstrates potential for significant brain penetration and is initially being developed for obesity treatment. The study, which marks the first human dosing of BGE-102, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Preclinical models have shown promising results, highlighting robust weight loss when BGE-102 is used as a monotherapy or in combination with GLP-1 receptor agonists. BioAge Labs anticipates initial data from the study's single ascending dose (SAD) phase by the end of 2025. The company plans to conduct a proof-of-concept study in 2026, with top-line results expected by the end of that year.